This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| ICER | |
|---|---|
| Name | Institute for Clinical and Economic Review |
| Abbreviation | ICER |
| Formation | 2006 |
| Type | Nonprofit organization |
| Headquarters | Boston, Massachusetts |
| Region served | United States |
| Leader title | President |
| Leader name | Steven D. Pearson |
ICER
ICER is an independent non‑profit research organization that produces comparative value assessments of pharmaceuticals, medical devices, and clinical interventions. It combines elements of clinical epidemiology, health economics, and outcomes research to inform decision‑making by payers, providers, and patient organizations. ICER's reports have influenced coverage determinations, pricing negotiations, and public debates involving major stakeholders such as Centers for Medicare & Medicaid Services, Food and Drug Administration, and national payer coalitions.
ICER defines itself as an independent body that evaluates clinical effectiveness and cost‑effectiveness of health technologies to guide value‑based pricing and coverage. Its stated purposes include informing health insurance benefit design, supporting evidence‑based formularies used by entities like Blue Cross Blue Shield Association and Kaiser Permanente, and providing convening forums with patient groups such as National Organization for Rare Disorders and advocacy organizations like American Cancer Society. The organization employs frameworks intended to translate comparative effectiveness findings into price benchmarks relevant to stakeholders including private payers, state Medicaid agencies, and federal agencies like Centers for Medicare & Medicaid Services.
Founded in 2006 by clinicians and health economists, ICER emerged amid contemporaneous efforts by institutions such as Institute for Healthcare Improvement and RAND Corporation to formalize value assessment. Early work paralleled initiatives by National Institute for Health and Care Excellence in the United Kingdom and by academic groups at Harvard Medical School and University of Washington. Over time ICER expanded from concise assessments to comprehensive evidence reports, adding stakeholder engagement processes similar to those used by Patient-Centered Outcomes Research Institute. High‑visibility reports on treatments for conditions addressed by companies like Novartis, Gilead Sciences, Biogen, and Amgen have drawn attention from lawmakers including members of United States Congress and regulators at the Food and Drug Administration.
ICER uses systematic literature review methods akin to standards from Cochrane Collaboration and health technology assessment techniques referenced by World Health Organization. Its analytical core combines meta‑analysis of randomized controlled trials and observational studies with decision‑analytic modeling using quality‑adjusted life years (QALYs) and incremental cost‑effectiveness ratios influenced by methodologies from Drummond and textbooks used at institutions like Johns Hopkins Bloomberg School of Public Health. The organization convenes independent advisory panels featuring clinicians from centers such as Mayo Clinic, health economists from universities like Yale University and University of Pennsylvania, and patient representatives from groups including Alzheimer's Association. ICER employs scenarios and sensitivity analyses and reports price benchmarks using thresholds that echo those debated by scholars at Harvard School of Public Health and policy analysts associated with Brookings Institution.
ICER's reports are used by health technology assessment units in payer organizations including Aetna, pharmacy benefit managers like Express Scripts, and state health technology assessment programs in states such as Washington (state). Hospitals and health systems including Cleveland Clinic and academic medical centers reference ICER findings when developing clinical pathways and formulary policies. Patient advocacy groups such as American Diabetes Association and specialty societies like American Society of Clinical Oncology have engaged with ICER reviews to influence research agendas, coverage guidance, and comparative effectiveness priorities.
ICER has faced critique from pharmaceutical firms including Pfizer and Roche, patient advocates including Lupus Foundation of America, and policy commentators at outlets linked to Heritage Foundation for reliance on QALYs, which some argue disadvantage rare disease populations and older adults. Debates echo earlier controversies experienced by National Institute for Health and Care Excellence and invoke legal and ethical discussions involving institutions like U.S. Department of Health and Human Services and scholars at Georgetown University. Critics have questioned transparency of modeling assumptions, stakeholder engagement timelines, and potential influence on pricing strategies by private payers such as UnitedHealth Group.
ICER's influence is visible in negotiated price concessions, supplemental rebate arrangements, and coverage restrictions announced by insurers and pharmacy benefit managers. Policymakers in Massachusetts and federal legislators have cited ICER analyses during hearings alongside testimony from executives of firms like Merck and economist witnesses from American Enterprise Institute. Its value benchmarks have informed value‑based contracting pilots between manufacturers and payers, mirroring contract experiments described in literature from Brookings Institution and Commonwealth Fund.
Related concepts include health technology assessment frameworks used by National Institute for Health and Care Excellence, cost‑utility analysis practiced at University of York, and value‑based pricing models discussed by analysts at Organisation for Economic Co‑operation and Development. Common metrics and tools referenced alongside ICER work include quality‑adjusted life years (QALYs), incremental cost‑effectiveness ratios (ICER thresholds as a general metric), budget‑impact analysis used by Institute for Healthcare Improvement, and real‑world evidence approaches developed with partners such as FDA's Sentinel System.
Category:Health technology assessment organizations